Medline Inc. (MDLN) is a Healthcare stock trading at $38.89 (as of 2026-07-20), with a market capitalization of $32.08B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Medline Inc. manufactures medical-surgical and related products for hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes in the U.S. and internationally. It operates through two segments: Medline Brand, which procures and makes products across surgical solutions, front line care, and laboratory/diagnostics, and Supply Chain Solutions.
Medline manufactures and sells medical-surgical products to hospitals, surgery centers, physician offices, post-acute facilities, and nursing home sites, earning revenue by procuring and manufacturing products through its Medline Brand segment and by supplying products through its Supply Chain Solutions segment.
Medline’s profit model combines in-house procurement and manufacturing of med-surg products (Medline Brand) with product supply for care sites (Supply Chain Solutions), so results depend on how effectively it sources, manufactures, and supplies medical products to these facilities.
Business quality (Weak): Clear two-segment business description, but no segment-level revenue split was provided, so the segment revenue view cannot be quantified here.
| Price | $38.89 |
| Market Cap | $32.08B |
| Price / Book | 1.66 |
| FCF Yield | 2.8% |
| DCF Value (model) | $16.72 |
| DCF Upside vs Price | -57.0% |
| Revenue (TTM) | $28.43B |
| Net Margin | 4.1% |
| Revenue Growth (YoY) | 10.7% |
| FCF Growth (YoY) | -45.9% |
| Altman Z-Score | 2.17 (grey) |
| Sector P/E (Healthcare) | 21.1 |
| Industry P/E (Medical Equipment) | 30.6 |
| Top Institutional Holder | Carlyle Group Inc. ($8.33B) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | James Boyle |
| Employees | 43,000 |
| Country | US |
| IPO Date | 2025-12-17 |
Data as of 2026-07-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.